South Korean SGLT-2/metformin combo 'could go global'

Daewoong Pharmaceutical (KRX: 069620) has already won approvals for its indigenous therapies - sodium–glucose linked transporter-2 (SGLT-2) inhibitor Envlo (enavogliflozin) and its metformin combination drug Envlomet - in South Korea.

As prescription trends tilt in favor of SGLT-2 combination therapies globally, the domestic innovator has an opportunity to compete with the established SGLT-2 combination therapies from multinational companies, says the data and analytics provider GlobalData.

"Daewoong is trying to expand to various emerging international markets, thereby laying the foundation to enter the global markets"With the SGLT-2 inhibitors offering concomitant cardiovascular and renal benefits, their preference has increased in the treatment algorithm of diabetes with cardiovascular and renal co-morbidities or even as preventive therapy in patients predisposed to these complications.